headermask image

header image

New Drug Slows Thyroid Cancer

July 3, 2008 – 8:50 pm

Experimental drugs that prevent the formation of tumors and blood vessel slows progress Metastatic of thyroid cancer in some patients, an international study finds.

93 patients with cancer progressing rapidly, and 49 had responded positively to treatment with motesanib diphosphate. These 49 patients, 14 per cent of the tumors that were reduced to 35 tumors has been installed for more than 24 weeks. Average survival free of progress towards 40 weeks.

Genetic analysis revealed that 25 patients drugs and the response was better in the States with a leap known as the braf v600e in those tumors without a breakthrough. Further research in this context, there is a genetic, the researchers said.

“Found that patients whose tumors have a certain surge was likely to respond to drugs is an example of where we would like to head in our research,” study author Dr. Steven I. Sherman, Chairman and Professor of Department of endocrine neoplasia and hormonal disorders at the University of Texas Anderson Media Division at the Centre Cancer, said in a prepared statement.
Thyroid Cancer
“This is the first of thyroid cancer among various tests to identify changes that could allow us to individualize or personal treatment.”

Study, published in the July 3 issue of the New England Journal of Medicine, and sponsorship of drug maker amgen

Motesanib diphosphate - vegf Manie - targets of a protein called vascular growth factor membrane (vegf), which plays a critical role in the formation of new blood vessels that allow for the growth and spread of tumors.

At present, there are few treatment options for Metastatic cancer of the thyroid gland.

“There is no standard procedure for accepting chemotherapy Metastatic differentiated advanced thyroid cancer, and response rates have typically been 25% or less,” Sherman said. “Most patients who are treated with systemic chemotherapy, because of limited benefit rarely justifies any side effects. Treatment of thyroid cancer has been completely unmet needs”

ugra | Cancer | Comments (0)

Smokeless Tobacco Products Do Raise Cancer Risk

July 3, 2008 – 8:45 pm

Smoke tobacco products (STPS), which includes products such as tobacco and Cm Chew, is used to increase risk of cancer - just not as much as you smoking.

I say that and researchers throughout the world to study patterns of use of Sao Tome and Principe and the associated risk of cancer.

Reporting in the July???? The issue of cancer tumors, a team led by Dr. Paolo boffeta, the International Agency for Research on Cancer in France, and noted that the Smoke tobacco products containing more than 30 carcinogens, including nitrosamines and minerals.

Analysis of studies from around the world and found that Sao Tome and Principe users had 80 percent of the total increased risk of cancer of the mouth and by 60% and increased risk of cancer esophageal. They also had a similar increase in risk of pancreatic cancer. European studies indicate any increased risk of lung cancer among users of Sao Tome and Principe, but American Studies indicate the presence of 80% increased risk of lung cancer, the panel said.

Cancer rates associated Smoke tobacco products differ between countries. For example, more than 50 per cent of cancers affecting the mouth, India and Sudan due to the Smoke tobacco products, compared with 4% in the U.S.

Results published in a special edition of the magazine devoted to lung cancer.
Tobacco
Overall, the studies do not support a strong link between the Smoke tobacco products cancer, the authors said, did not recommend a smoke to be a substitute for smoking.

“We do not intend to use addresses, frankly, than tobacco smoke to reduce the risk of smoking tobacco - for example, by encouraging smokers to smoke or switch to products through the introduction of these products in the population where this habit is not prevalent,” the The researchers concluded.

“However, many of the conclusions that can be reached based on data available … the risk of cancer, especially the mouth and lung cancer, and perhaps less in tobacco smoke users in the United States of America and Northern Europe from smoking, the risk Cancer higher in the smoke of those employed in non-beneficiaries from any form of tobacco, “wrote the panel. “Available data for the possible benefit from the transition from smoking to tobacco smoke comes from several studies and models from the United States and Sweden.”

Another article in the July issue of???? The tumors indicates that the DNA testing of certain vital that could help in assessing the risk of lung cancer in people exposed to smoke user.

Many of carcinogens in cigarette smoke are known to cause DNA lesions about DNA and invited many of the carcinogens that are known signatures to leave a unique cancer-related genes in the form of specific changes in specific places, and noted Dr. Ahmed and Dr. besaratinia Gerd pfeifer, the Research Institute for the Beckmann from the city of hope and National Medical Center in Duarte, Calif

She noted that a technique called DNA footprinting scourge, in conjunction with mutagenicity analysis, and is currently being used to find a carcinogenic material signatures. They proposed that this method is used in cancer - the relevant genes, which often change their smoke related lung cancer.

In fact, this method has been used successfully to find nearly regarding various derived from smoke carcinogens, the researchers said.

ugra | Baby, smoking | Comments (0)